From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua ...

For optometrists, 2026 provides ample opportunity to continue the charge in advancements in dry eye, artificial intelligence ...

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and ...

The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial ...

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million ...

Nanoscope Therapeutics has received Pioneering Regenerative Medical Product (Sakigake) and Orphan Drug designations for ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...

Analysis of 20 years of data highlights differences in reimbursement trends across ophthalmology subspecialties and practice ...

Hemodialysis significantly alters anterior and posterior eye segments, affecting parameters like anterior chamber depth, lens ...